AlphaCrest Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

AlphaCrest Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,642	Closed	-$476K	–	1202
2022 Q3	$476K	Sell	17,642 -5,398	-23%	-$110K	0.03%	994
2022 Q2	$318K	Buy	+23,040	New	+$355K	0.02%	1102
2022 Q1	–	Sell	-34,910	Closed	-$570K	–	1438
2021 Q4	$570K	Buy	+34,910	New	+$582K	0.02%	1054
2021 Q3	–	Sell	-17,700	Closed	-$525K	–	1406
2021 Q2	$525K	Hold	17,700	–	–	0.02%	942
2021 Q1	$495K	Sell	17,700 -6,300	-26%	-$174K	0.03%	798
2020 Q4	$680K	Buy	24,000 +12,900	+116%	+$334K	0.06%	484
2020 Q3	$279K	Buy	+11,100	New	+$291K	0.03%	898
2019 Q3	–	Sell	-17,600	Closed	-$228K	–	1354
2019 Q2	$228K	Buy	17,600 +5,700	+48%	+$71.8K	0.02%	941
2019 Q1	$188K	Buy	+11,900	New	+$206K	0.03%	784

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AlphaCrest Capital Management's RVNC Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 17,642 shares — an estimated $476K sold.

AlphaCrest Capital Management first reported a position in RVNC in Q1 2019 and held it in 9 quarters. The position peaked at $680K in Q4 2020. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

AlphaCrest Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 17,642 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $476K.
AlphaCrest Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2019 and held it in 9 quarters.
AlphaCrest Capital Management's Revance Therapeutics, Inc. position peaked at $680K in Q4 2020.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.